What is REGEN BIOPHARMA PFD A's earnings per share (EPS)?

REGEN BIOPHARMA PFD A (RGBPP) reported diluted earnings per share of -$0.05 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

REGEN BIOPHARMA PFD A (RGBPP) Financials

RGBPP

Trailing 12 months to June 30, 2026

Revenue $237K 0.0% YoY

Net Income -$1.2M -22.7% YoY

EPS (Diluted) -$0.05 FY2025 annual

Operating Cash Flow -$445K -3.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 30, 2026 Reported Aug 17, 2026 Currency USD FYE September

Newest figures come from the 10-Q for Q3 FY2026, filed Aug 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RGBPP SEC filings page.

REGEN BIOPHARMA PFD A (RGBPP) reported $237K in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RGBPP FY2025 2026-10-03

The company remains a very small-revenue operation whose improving operating loss has not translated into better net results or balance-sheet strength.

In FY2025, the operating loss narrowed, yet net loss reached $1.3M as interest expense rose to $158K; core costs improved, but below-operating charges erased that progress. This separates improvement inside the operation from deterioration in the result ultimately attributable to shareholders.

Liabilities totaled $6.6M against assets of $274.6K in FY2025, so obligations were vastly larger than recorded resources. The current ratio was 0.0x, while reported liquidity equaled 2.2 months of the latest annual operating outflow; short-term resources therefore did not cover near-term claims.

Revenue was essentially unchanged at $236.6K in both FY2024 and FY2025, so the narrower operating loss reflects internal cost movement rather than expansion of the business base. Operating cash outflow fell from $751.5K to $383.6K, a cash-flow improvement that did not translate into a better bottom line.

Financial Health Signals

Financial health score not available

REGEN BIOPHARMA PFD A does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

REGEN BIOPHARMA PFD A passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

REGEN BIOPHARMA PFD A reported a net loss of $1.3M while operations used $384K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

REGEN BIOPHARMA PFD A reported an operating loss of $339K against $158K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$59K

YoY0.0%

QoQ0.0%

REGEN BIOPHARMA PFD A generated $59K in revenue in Q3 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Net Income

-$638K

YoY-281.2%

QoQ-164.3%

REGEN BIOPHARMA PFD A reported -$638K in net income in Q3 2026. This represents a decrease of 281.2% from the same quarter a year earlier. Against the prior quarter it is down 164.3%.

EPS (Diluted)

$0.00

REGEN BIOPHARMA PFD A earned $0.00 per diluted share (EPS) in Q3 2026.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$239

YoY-86.4%

QoQ-11.8%

5Y CAGR-73.7%

10Y CAGR-47.1%

REGEN BIOPHARMA PFD A held $239 in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

1.68B

5Y CAGR-18.2%

REGEN BIOPHARMA PFD A had 1.68B shares outstanding in Q3 2026.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin

41.5%

YoY+110.5pp

REGEN BIOPHARMA PFD A's operating margin was 41.5% in Q3 2026, reflecting core business profitability. This is up 110.5 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q3 2026.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending

QoQ-100.0%

REGEN BIOPHARMA PFD A reported no research and development spending in Q3 2026. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

RGBPP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RGBPP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$237K	$237K0.0%	$237K0.0%	$237K+88.5%	$126K+105.1%	$61K-44.4%	$110K0.0%	$110K+10.0%	$100K-9.1%	$110K+10.0%	$100K-47.9%	$192K	$0	N/A
R&D Expenses	$224K	$12K-92.4%	$154K-27.6%	$212K+34.2%	$158K+330.8%	$37K+176.3%	$13K-70.9%	$46K-87.8%	$374K-67.4%	$1.1M+71.3%	$671K+137.7%	$282K+1082.8%	$24K+184.3%	$8K
SG&A Expenses	$296K	$75K	$0	$0-100.0%	$28K-76.5%	$119K-52.1%	$250K-50.1%	$501K-32.7%	$744K-9.5%	$822K	N/A	N/A	N/A	$263K
Operating Income	-$804K	-$339K+18.9%	-$417K+39.3%	-$687K-102.3%	-$340K-69.2%	-$201K+4.1%	-$209K	N/A	N/A	-$2.5M	N/A	N/A	N/A	-$320K
Interest Expense	$170K	$158K+118.5%	$72K+23.7%	$59K-57.8%	$139K-56.1%	$316K-5.2%	$333K+13.0%	$295K+13.9%	$259K+162.2%	$99K+255.1%	$28K+28.3%	$22K+880.5%	$2K	$0
Income Tax	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.2M	-$1.3M-90.7%	-$668K-157.8%	$1.2M-52.7%	$2.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$355K
EPS (Basic)	N/A	-$0.05+68.8%	-$0.16-155.2%	$0.29-59.2%	$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$0.05	-$0.16-155.2%	$0.29	$0.71	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	24M	4M+16.2%	4M	3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$59K0.0%	$59K0.0%	$59K0.0%	$59K0.0%	$59K0.0%	$59K0.0%	$59K0.0%	$59K-48.0%
R&D Expenses	$0	$2K	$210K	$12K-65.0%	$0-100.0%	$0-100.0%	$0-100.0%	$34K-5.1%
SG&A Expenses	$14K-54.9%	$32K+140.5%	$232K+1641.6%	$18K+146.3%	$31K+86.1%	$13K+42.2%	$13K+7.2%	-$38K-4.5%
Operating Income	$25K+160.2%	-$154K-35.6%	-$552K-798.7%	-$123K-44.1%	-$41K+62.3%	-$113K-12.1%	-$61K+50.0%	-$85K-44.5%
Interest Expense	$30K+23.2%	$27K+22.7%	$27K+4.7%	$86K+328.5%	$25K+40.4%	$22K+30.9%	$25K+42.7%	$20K+33.1%
Income Tax	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	-$638K-281.2%	$992K+5225.2%	-$968K-87.8%	-$572K-116.1%	-$167K-28.6%	-$19K+84.2%	-$515K-255.6%	-$265K+18.5%
EPS (Basic)	$0.00+100.0%	$0.00	-$0.01+92.3%	-$0.02+66.7%	-$0.01+66.7%	$0.00+100.0%	-$0.13-225.0%	-$0.06+40.0%
EPS (Diluted)	$0.00	$0.00	-$0.01	-$0.02	-$0.01	$0.00	-$0.13	-$0.06+40.0%
Diluted Shares (Avg)	616M	185M	100M	N/A	24M	22M	4M	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EBITDA.

RGBPP Balance Sheet

RGBPP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$275K+70.5%	$161K-54.4%	$354K-36.7%	$559K-53.9%	$1.2M+883.9%	$123K+24.3%	$99K-52.6%	$209K-77.9%	$944K+195.7%	$319K+44.9%	$220K+1969.0%	$11K-90.8%	$116K
Current Assets	$275K+91.6%	$143K+9.4%	$131K-61.0%	$336K-66.2%	$994K+863.1%	$103K+30.5%	$79K+85.0%	$43K-91.1%	$478K+130.7%	$207K+234.2%	$62K+482.4%	$11K-90.8%	$116K
Cash & Equivalents	$70K+9614.4%	$716-99.4%	$121K+136.4%	$51K-93.0%	$727K	$0-100.0%	$8K-2.0%	$8K-97.0%	$270K+987.6%	$25K-35.7%	$39K	$0-100.0%	$116K
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$205K+115.9%	$95K	$0-100.0%	$254K+19.3%	$213K+106.6%	$103K+45.0%	$71K	$0	$0-100.0%	$83K	N/A	N/A	N/A
Long-Term Investments	$0-100.0%	$18K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$6.6M+21.9%	$5.4M-1.5%	$5.5M-36.5%	$8.6M-41.5%	$14.7M+97.1%	$7.5M-32.2%	$11.0M+18.0%	$9.3M+50.6%	$6.2M+583.6%	$906K+185.3%	$318K+126.4%	$140K	$0
Current Liabilities	$6.6M+21.9%	$5.4M+1.3%	$5.3M-38.2%	$8.6M-41.5%	$14.7M+97.1%	$7.5M-32.2%	$11.0M+26.9%	$8.7M+47.9%	$5.9M+633.6%	$799K+151.6%	$318K+126.4%	$140K	$0
Non-Current Liabilities	$0	$0-100.0%	$150K	$0	$0	$0-100.0%	$5K-99.2%	$657K+97.7%	$332K+210.5%	$107K	$0	$0	$0
Total Equity	-$6.3M-20.4%	-$5.2M-2.2%	-$5.1M+36.5%	-$8.0M+40.4%	-$13.5M-83.9%	-$7.3M+32.8%	-$10.9M-19.6%	-$9.1M-73.7%	-$5.3M-794.8%	-$587K-503.9%	-$97K+25.0%	-$130K-211.8%	$116K
Retained Earnings	-$21.7M-6.2%	-$20.4M-3.4%	-$19.7M+5.5%	-$20.9M+10.5%	-$23.3M-40.8%	-$16.6M+17.1%	-$20.0M-14.6%	-$17.5M-37.0%	-$12.7M+37.0%	-$20.2M-62.1%	-$12.5M-875.6%	-$1.3M-144.8%	-$522K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$288K+46.1%	$260K+53.5%	$237K+23.9%	$275K+70.5%	$197K+15.7%	$169K+20.4%	$191K+20.0%	$161K-54.4%
Current Assets	$288K+60.6%	$260K+71.5%	$237K+36.5%	$275K+91.6%	$179K+17.5%	$152K+23.3%	$174K+22.5%	$143K+9.4%
Cash & Equivalents	$239-86.4%	$271-84.6%	$5K+3291.1%	$70K+9614.4%	$2K-97.2%	$2K-97.7%	$135-99.9%	$716-99.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$287K+62.1%	$260K+73.5%	$232K+89.9%	$205K+115.9%	$177K+163.8%	$150K+276.9%	$122K+894.5%	$95K
Long-Term Investments	$0-100.0%	$0	$0	$0-100.0%	$18K	$0	$0	$18K
Total Liabilities	$6.2M+2.5%	$5.6M-4.2%	$6.8M+16.0%	$6.6M+21.9%	$6.0M+12.9%	$5.9M+10.4%	$5.9M+8.7%	$5.4M-1.5%
Current Liabilities	$6.2M+2.5%	$5.6M-4.2%	$6.8M+16.0%	$6.6M+21.9%	$6.0M+12.9%	$5.9M+13.4%	$5.9M+11.9%	$5.4M+1.3%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%
Total Equity	-$5.9M-1.1%	-$5.4M+6.0%	-$6.6M-15.7%	-$6.3M-20.4%	-$5.8M-12.8%	-$5.7M-10.1%	-$5.7M-8.3%	-$5.2M-2.2%
Retained Earnings	-$22.3M-5.6%	-$21.7M-3.4%	-$22.7M-8.3%	-$21.7M-6.2%	-$21.1M-3.8%	-$21.0M-3.6%	-$20.9M-4.1%	-$20.4M-3.4%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

RGBPP Cash Flow Statement

RGBPP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$445K	-$384K+49.0%	-$752K-332.1%	-$174K+71.3%	-$607K+46.3%	-$1.1M-6165.6%	$19K+103.9%	-$482K	N/A	-$1.9M	N/A	N/A	N/A	N/A
Stock-Based Compensation	N/A	N/A	$13K-96.3%	$348K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$25K-94.9%	$495K	$0-100.0%	$50K+968.5%	-$6K	$0	N/A	N/A	N/A	N/A
Financing Cash Flow	$444K	$452K-28.3%	$631K+159.0%	$244K+359.2%	-$94K-106.9%	$1.4M+5243.8%	-$27K-106.1%	$432K	N/A	$2.1M	N/A	N/A	N/A	$400K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$24K+57.0%	-$63K+37.5%	-$198K-198.2%	-$160K+22.8%	-$56K+67.6%	-$101K+51.6%	-$66K+59.1%	-$207K-785.7%
Financing Cash Flow	$24K-57.1%	$59K-42.7%	$133K+102.1%	$228K+55.9%	$56K-64.2%	$103K-36.9%	$66K-60.3%	$146K+1.7%

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

RGBPP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RGBPP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Margin	-143.1%	-176.4%	-290.4%	-270.6%	-328.1%	-190.3%	N/A	N/A	-2282.6%	N/A	N/A	N/A	N/A
Net Margin	-538.8%	-282.5%	488.9%	1946.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-306.3%
Return on Assets	-464.1%-49.2pp	-414.9%-741.9pp	327.1%-110.1pp	437.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-306.3%
Current Ratio	0.040.0x	0.030.0x	0.020.0x	0.040.0x	0.07+0.1x	0.010.0x	0.010.0x	0.00-0.1x	0.08-0.2x	0.26+0.1x	0.20+0.1x	0.08	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.00
Asset Turnover	0.86-0.6x	1.47+0.8x	0.67+0.4x	0.22+0.2x	0.05-0.8x	0.89-0.2x	1.11+0.6x	0.48+0.4x	0.12-0.2x	0.31-0.6x	0.87+0.9x	0.00	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Margin	41.5%+110.5pp	-260.2%	-933.9%	-207.3%	-69.0%	-191.9%	-103.9%	-143.9%
Net Margin	-1079.8%	1679.4%	-1638.6%	-964.3%	-283.2%	-32.8%	-872.6%	-446.2%
Return on Assets	-221.8%-136.8pp	381.2%+392.6pp	-408.2%-139.0pp	-208.4%-44.0pp	-85.0%-8.5pp	-11.4%+75.6pp	-269.3%-178.4pp	-164.5%-72.5pp
Current Ratio	0.050.0x	0.050.0x	0.030.0x	0.040.0x	0.030.0x	0.030.0x	0.030.0x	0.030.0x
Asset Turnover	0.21-0.1x	0.23-0.1x	0.25-0.1x	0.22-0.2x	0.300.0x	0.35-0.1x	0.31-0.1x	0.370.0x

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
REGEN BIOPHARMA PFD A RGBPP	FY2025	$237K	-$1.3M	N/A	N/A	—
OCEAN BIOMEDICAL INC OCEA	FY2024	N/A	N/A	N/A	$6.8M	—
AYALA PHARMACEUTICALS INC ADXS	FY2023	$13K	-$48.1M	N/A	$25.7M	—
GALERA THERAPEUTICS INC GRTX	FY2025	N/A	N/A	N/A	$6.5M	—

Where REGEN BIOPHARMA PFD A Ranks

Frequently Asked Questions

What is REGEN BIOPHARMA PFD A's annual revenue?

REGEN BIOPHARMA PFD A (RGBPP) reported $237K in total revenue for fiscal year 2025. That is unchanged from the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is REGEN BIOPHARMA PFD A's revenue growing?

REGEN BIOPHARMA PFD A (RGBPP) revenue was essentially unchanged year-over-year, at $237K in fiscal year 2025 against $237K the year before.

Is REGEN BIOPHARMA PFD A profitable?

No, REGEN BIOPHARMA PFD A (RGBPP) reported a net income of -$1.3M in fiscal year 2025.

What is REGEN BIOPHARMA PFD A's operating cash flow?

REGEN BIOPHARMA PFD A (RGBPP) recorded an outflow of $384K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are REGEN BIOPHARMA PFD A's total assets?

REGEN BIOPHARMA PFD A (RGBPP) had $275K in total assets as of fiscal year 2025, including both current and long-term assets.

How much does REGEN BIOPHARMA PFD A spend on research and development?

REGEN BIOPHARMA PFD A (RGBPP) invested $12K in research and development during fiscal year 2025.

How many shares does REGEN BIOPHARMA PFD A have outstanding?

REGEN BIOPHARMA PFD A (RGBPP) had 108M shares outstanding as of fiscal year 2025.

What is REGEN BIOPHARMA PFD A's current ratio?

REGEN BIOPHARMA PFD A (RGBPP) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is REGEN BIOPHARMA PFD A's return on assets (ROA)?

REGEN BIOPHARMA PFD A (RGBPP) had a return on assets of -464.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does REGEN BIOPHARMA PFD A's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, REGEN BIOPHARMA PFD A (RGBPP) held $70K in cash, cash equivalents and investments, and reported an operating cash outflow of $384K over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is REGEN BIOPHARMA PFD A's debt-to-equity ratio negative or not reported?

REGEN BIOPHARMA PFD A (RGBPP) has negative shareholder equity of -$6.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is REGEN BIOPHARMA PFD A's Piotroski F-Score?

REGEN BIOPHARMA PFD A (RGBPP) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are REGEN BIOPHARMA PFD A's earnings high quality?

REGEN BIOPHARMA PFD A (RGBPP) reported a net loss of $1.3M while operations used $384K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can REGEN BIOPHARMA PFD A cover its interest payments?

REGEN BIOPHARMA PFD A (RGBPP) reported an operating loss of $339K against $158K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.